Q&As

Is there is a distinction between proactive and reactive communication when speaking with patient advocacy groups?

read titleRead full title
Published on LexisPSL on 20/12/2017

The following Life Sciences Q&A provides comprehensive and up to date legal information covering:

  • Is there is a distinction between proactive and reactive communication when speaking with patient advocacy groups?

The European Federation of Pharmaceutical Industries and Associations Code of Practice on Relationships between the Pharmaceutical Industry and Patient Organisations provides general principles and a template agreement for interactions between pharmaceutical companies and patient organisations. Interactions with patient advocacy groups are permitted to the extent that such interactions do not constitute promotion (see

Related documents:

Popular documents